Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amgen Inc updates on phase 3 decision trial of NEXAVAR


Wednesday, 23 Apr 2014 09:20pm EDT 

Amgen Inc:Says that its subsidiary published online results from the Phase 3 DECISION trial.Which demonstrated that NEXAVAR(sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma.Says that is refractory to radioactive iodine treatment lived without their disease worsening. 

Company Quote

161.8
0.22 +0.14%
3:14pm EDT